96413 — chemotherapy administration, IV infusion technique; up to 1 hour, single or initial substance/drug. 96415 — each additional hour (list separately in addition to 96413). The pair is used together when the chemo IV infusion exceeds an hour. The first administration of the encounter is always 96413 even if the infusion is under 60 minutes. Each additional hour is 96415, where “additional hour” counts only if at least 31 minutes spilled into that hour. A second sequential chemo drug at the same encounter is 96417, not a second 96413.
The 96413/96415 pair lives in the AMA CPT 96401-96549 chemotherapy and other highly complex drug or highly complex biologic agent administration family. Authority is the current-year AMA CPT Professional Edition; Medicare reimbursement guidance is in CMS Internet-Only Manual Publication 100-04, Chapter 12, §30.5 (Drug Administration Services). The NCCI Policy Manual Chapter XI covers chemotherapy administration coding edits, including the prohibition on billing more than one initial-administration code per encounter.
Despite the word “chemotherapy” in the code descriptor, per AMA CPT introductory guidelines to the 96401-96549 section the family covers antineoplastic agents, monoclonal antibodies used as chemotherapy, biologic response modifiers, and other highly complex agents — the determining factor is the indication and clinical complexity, not the molecular class. The same drug can map to 96413 for an oncology indication and to 96365 for a non-oncology indication. The most important practical effect: oncology buy-and-bill claims for cytotoxics, monoclonals (rituximab, daratumumab, trastuzumab), antibody-drug conjugates (Kadcyla J9354, Enhertu J9358, Adcetris J9042), and immune checkpoint inhibitors (Keytruda J9271, Opdivo J9299, Yervoy J9228, Tecentriq J9022, Imfinzi J9173) all use the 96413 family.
96415 is an AMA add-on code (designated with the + symbol) and may only be reported in addition to 96413. It cannot stand alone on a claim. Add-on codes are exempt from most NCCI procedure-to-procedure edits, so modifier 59 is generally not required when 96415 follows 96413 at the same encounter.
The decision tree is built around the AMA CPT “initial vs sequential vs concurrent” hierarchy: only one initial-administration code per encounter, and the chemotherapy family ranks higher than the therapeutic-infusion family. If a patient gets a chemo infusion followed by a hydration line, the chemo is the initial code (96413) and the hydration is sequential (96361). The hierarchy applies even when the chemo drug is given second in time — the higher-ranked drug class still claims the initial-administration code.
The single largest source of 96413 denials in 2024-2025 audit data is billing 96413 for a biologic given for a non-cancer indication. A rituximab infusion for rheumatoid arthritis is coded 96365 + 96366 (therapeutic) even though the molecule is identical to the oncology product J9312. The diagnosis on the claim and the prior-authorization indication drive the administration-code choice — not the J-code.
The chemo administration hierarchy is an AMA CPT construct, so commercial payers and Medicare align almost universally on 96413/96415 sequencing. Divergence shows up in two places: prior-authorization scrutiny on biologics that could plausibly map to either family, and the rate-per-unit assigned to the codes on each payer's fee schedule.
| Payer | Aligned with AMA hierarchy? | Notes |
|---|---|---|
| Medicare (Part B) | Yes | Source-of-truth payer. CMS IOM Pub 100-04 Ch.12 §30.5 incorporates the AMA chemo hierarchy verbatim. MAC LCDs for chemo administration restate the 31-minute rule and the “one initial code per encounter” rule. Edit cycle rejects a second 96413 on the same date of service. |
| UnitedHealthcare | Yes | Aligns with CMS at adjudication. OptumRx prior-auth approvals for oncology biologics flag the administration code on the PA letter; mismatches between PA-approved code and claim code trigger pended review. UHC commercial fee schedule pays 96413 at a meaningfully higher RVU than 96365. |
| Aetna (CVS Health) | Yes | Aligns with CMS. Aetna oncology medical policies (e.g., for Rituxan, Herceptin, Keytruda) reference the chemo administration family directly. CVS Specialty dispensing reports include the expected admin code for cross-check. |
| Cigna / Express Scripts | Yes | Aligns with CMS. Accredo specialty pharmacy ships oncology product directly to the practice for buy-and-bill; admin code is billed on the medical claim. Cigna oncology medical policies are the most explicit about indication-driven admin coding (chemo for cancer, therapeutic for non-cancer). |
| Humana | Yes | MA-heavy book follows CMS by default. CenterWell Specialty supplies oncology biologics under Humana MA; admin code billed on the medical claim is reconciled against the dispensing record. Humana commercial PPO aligns to AMA hierarchy with same enforcement posture as Medicare. |
| Denial pattern | What it means | Fix / appeal language |
|---|---|---|
| 96413 billed for non-chemo biologic (CARC 11 / 50) | Claim shows 96413 with a diagnosis code that does not support an oncology indication (e.g., M05/M06 rheumatoid arthritis paired with J9312 rituximab). Medicare and commercial payers read this as wrong administration family. | Rebill the encounter with 96365 + 96366 (therapeutic IV infusion family) for the same J-code. Appeal language: “The administered product is rituximab (J9312) for the non-cancer indication [diagnosis], reportable under the AMA CPT 96365 therapeutic infusion family per the indication-driven hierarchy. The corrected claim restructures the administration line as 96365 + 96366 x N for the [X]-hour infusion.” |
| 96415 billed without 96413 primary (CARC 107) | Add-on code submitted on its own line without the required parent code on the same encounter. NCCI rejects add-on codes that lack their primary procedure. | Add the 96413 line for the first hour. Appeal language: “96415 is an AMA add-on code that must be billed in conjunction with 96413. The corrected claim adds the 96413 primary for the first hour of the chemo IV infusion, with [N] units of 96415 for the additional hours.” |
| 96413 billed twice on same DOS (CARC 18 / NCCI MUE) | Two units of 96413 on the same encounter. AMA CPT permits only one initial-administration code per encounter, and the NCCI Medically Unlikely Edit for 96413 is 1. | Rebill with 96413 x 1 for the first chemo drug and 96417 x N for each additional sequential chemo drug. Appeal language: “Per AMA CPT 96401-96549 introductory guidelines and NCCI Policy Manual Ch.XI, only the first chemo administration of an encounter is reported with 96413; subsequent sequential drugs are reported with 96417 (or 96416 for concurrent). The corrected claim restructures the second drug as 96417 x 1.” |
| 96415 hour count wrong (CARC 16 / N/A) | Number of 96415 units submitted does not match the documented infusion start/stop time when the 31-minute rule is applied. Payer audits flag mismatches between the medical record and the claim. | Recompute hours: total minutes minus 60, then divide by 60 and round per the 31-minute rule. Resubmit with the corrected unit count. Appeal language: “Per AMA CPT 96415 guidance, additional hours are counted by the 31-minute rule. Documented infusion start/stop is [HH:MM] to [HH:MM] = [N] total minutes. After the initial hour billed as 96413, additional time was [M] minutes → [K] units of 96415. The corrected claim reports 96415 x [K].” |
| 96413 missing for short chemo infusion (under 31 min) | Practice omits 96413 thinking a sub-31-minute infusion does not warrant the “up to 1 hour” code, or substitutes 96409 (push) for a short infusion. | Bill 96413 for the first hour regardless of duration when the route is infusion (not push). Appeal language: “96413 is reported for the initial chemo IV infusion up to one hour. A 25-minute infusion still uses 96413 — the ‘up to 1 hour’ descriptor covers the full first hour, not a 31-minute minimum. The corrected claim adds the 96413 primary.” |
96413 is for IV infusion of a chemotherapy or highly-complex biologic agent — the determining factor is the indication and the complexity of administration, not the molecular class. Cytotoxics, monoclonal antibodies used to treat cancer (rituximab for NHL, daratumumab for myeloma), antibody-drug conjugates, and immune checkpoint inhibitors all map to 96413. The same drug administered for a non-cancer indication (rituximab for rheumatoid arthritis, infliximab for Crohn's) maps to 96365 — therapeutic infusion.
Per AMA CPT guidance, 96415 (each additional hour) is reported once for every full hour beyond the first, but the rounding rule is that infusion time of at least 31 minutes counts as an additional hour, and 30 minutes or less does not. So a 90-minute chemo infusion = 96413 + 96415 x 1. A 2-hour infusion = 96413 + 96415 x 1. A 2-hour 31-minute infusion = 96413 + 96415 x 2. Document start and stop times in the medical record.
96415 reports additional time on the SAME chemo drug. 96417 reports a SECOND sequential chemo drug at the same encounter. If the patient gets carboplatin over 2 hours then paclitaxel over 3 hours, that is 96413 (initial carbo) + 96415 (carbo hour 2) + 96417 (sequential paclitaxel). The two codes are not interchangeable: 96415 is more time on the same drug, 96417 is a new drug.
No. Only the first chemo administration of an encounter is 96413 (the initial code per the AMA infusion hierarchy). Each subsequent sequential chemo drug at the same encounter is coded as 96417 (sequential infusion of additional substance) or 96416 (concurrent infusion). Reporting 96413 twice on one encounter is a top denial pattern and is flagged by NCCI edits.
Only when used as a chemotherapy-class biologic — i.e., for an oncologic indication like non-Hodgkin lymphoma, chronic lymphocytic leukemia, or related hematologic malignancies. When rituximab is given for rheumatoid arthritis, pemphigus vulgaris, or another non-cancer indication, the administration is coded as a therapeutic IV infusion (96365 + 96366 for additional hours), not as chemo. The diagnosis on the claim drives the administration code choice.
Sequential = one drug finishes, the next drug starts through the same line (back-to-back, not overlapping). Concurrent = two drugs running through separate lines at the same time, or one drug running in the line while a second is piggy-backed in. Sequential additional chemo infusion = 96417. Concurrent additional chemo infusion = 96416. Most chemo regimens are sequential; concurrent administration is rare and usually involves a continuous-infusion product running alongside a bolus.
Generally no. 96415 is an add-on code (designated with the AMA + symbol) that does not require modifier 59 to be billed alongside the parent 96413, because add-on codes are exempt from most NCCI Procedure-to-Procedure edits. Modifier 59 may be needed in narrow cases involving separately identifiable encounters on the same calendar day or distinct sessions — most chairside reviewers should not append 59 routinely to 96415.
No. Anti-emetics (ondansetron, dexamethasone), antihistamines (diphenhydramine), and acetaminophen given before a chemo infusion are coded as therapeutic infusions or IV pushes (96365/96366 for infusion, 96374/96375 for push), not as chemo administration. They are sequential substances to the chemo drug and are reported separately. The chemo drug itself is the only line that uses the 96413/96415/96417 family.
All sources are publicly available federal publications or paraphrased from AMA / trade-association educational materials. AMA CPT code descriptors are reproduced under fair-use reference; full descriptors require an AMA CPT license. The methodology by which we resolve source disagreements is described in the Methodology.